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ABSTRACT 
Objectives: The aim of the study was to determine if adolescents with juvenile bleeding had polycystic ovarian syndrome 
(PCOS) and insulin resistance. 
Material and methods: The study was conducted in a group of 43 females aged 12–18 years, diagnosed with juvenile 
menorrhagia, and 37 healthy female adolescents aged 12–18 years. The study was conducted during the early follicular 
phase of the menstrual cycle. Menstrual cycle disturbances, acne and hirsutism were recorded. Ultrasound scan determining 
the condition of the ovaries was conducted. Laboratory tests of the glucose level, cholesterol, LDL and HDL cholesterol 
and triglycerides fraction, DHEAS, FSH, LH, insulin, SHGB, total testosterone, androstenedione, and free testosterone have 
been established. 
Results: The occurrence of regular menstrual cycles (30.23%, p = 0.006) was significantly lower in the juvenile bleeding 
group. Also, secondary amenorrhea was significantly more likely to be recognized in this group of females (p = 0.03). The 
concentration of FSH was considerably lower (p = 0.0002) in the group of adolescents with AUB. 
Conclusions: Adolescents with abnormal uterine bleeding (AUB) are often diagnosed with secondary amenorrhea, and 
PCOS. The group with a diagnosis of juvenile bleeding was also diagnosed with higher rates of insulin resistance.
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INTRODUCTION
Abnormal uterine bleeding (AUB), or juvenile bleeding, 
is defined as heavy bleeding with blood clots, lasting more 
than 7 days and often leads to anemia. Menstrual blood loss 
exceeds 80 mL [1–5].
It has been observed that abnormal menstrual bleeding 
occurs in approximately 20–30% of adolescent females, and 
one fifth experience features relating to AUB during their 
first period. It is estimated that 80% of adolescent bleeding 
occurs one to two years after menarche [3, 4].
Etiopathogenesis of juvenile bleeding has not yet 
been fully established. It is believed that heavy menstrual 
bleeding in adolescence has no organic etiology, but is 
due to a lack of ovulation and luteal insufficiency. In these 
cases, menstrual cycles are not yet regular, there are no 
premenstrual symptoms and bleeding may start without 
any signals indicating the approach of menstruation [4 –7].
It has also been suggested that juvenile bleeding may 
be associated with hormonal disorders such as polycystic 
ovarian syndrome (PCOS). It was observed that among some 
young women with PCOS, incidents of heavy menstrual 
bleeding had previously occurred [8].
Currently, there are only few results from large 
epidemiological studies which would affect the risk factors 
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of the polycystic ovarian syndrome. In studies conducted on 
small groups of women, a significantly higher incidence of 
PCOS was observed among women with low birth weight, 
premature start of puberty and the onset of menarche over 
15 years of age. A risk factor for PCOS is obesity and there 
are also observations being carried out on the genetics of 
this syndrome [9–12].
Heavy menstrual bleeding occurs frequently and 
can significantly impair the quality of life of adolescent 
females. Thorough analysis and research can help in 
revealing the causes of abnormal bleeding and prevent 
intensification of co-endocrine disorders such as acne, 
hirsutism, PCOS, metabolic syndrome and insulin resistance 
in future life [12–16]. 
Objectives
The aim of this research project was to assess the 
presence of polycystic ovarian syndrome and insulin 
resistance in females diagnosed with juvenile bleeding. 
MATERIALS AND METHODS
Study population
The study included 43 females aged between 12 and 
18 years old, who were diagnosed with abnormal uterine 
bleeding (AUB), and 37 healthy females of the same age 
range, who constituted the control group. All respondents 
gave written consent to carry out all the procedures included 
in the study protocol (in case of underage patient, consent 
was taken both from the participant and their parent or 
legal guardian). The study was approved by the Bioethics 
Committee of the Medical University of Silesia in Katowice 
(No. of consent KNW /0022/KBI/74/12).
Methods
All participants of the study had a gynecological 
assessment, which established menstrual cycles (length, 
regularity of menstrual cycle, presence of secondary 
amenorrhea and the length of menstrual bleeding). 
According to the American Society of Obstetricians 
and Gynecologists (ACOG), normal menstrual cycles in 
adolescent females last 21–45 days, and the duration 
of menstrual bleeding ≤ 7 days [14]. Heavy menstrual 
bleeding is defined as being > 80 mL [2, 4, 17]. Irregular 
menstrual cycles, are when the length of the cycle is shorter 
than 21 days (polymenorrhoea) or longer than 45 days 
(oligomenorrhoea) [17]. Secondary amenorrhea was defined 
as lack of menstrual bleeding for more than 6 months in 
those with a history of normal menstruation [18].
Clinical features of hyperandrogenism were based 
on the occurrence of features such as hirsutism, acne 
(diagnosed based on a subjective 10-step scale), and 
androgenetic alopecia. Hirsutism was assessed using the 
Ferriman and Gallwey scale and was diagnosed if the score 
was 8 or more points [7, 18]. In addition, between the 
3rd and 5th day of the menstrual cycle a transabdominal 
ultrasound scan was conducted to assess the structure and 
volume of the ovaries. The diagnosis of PCOS was based on 
the ESHRE/ASRM criteria. Assuming that the adolescents 
satisfied all three criteria, and had been assessed for at 
least two years after menarche [19–22]. All participants 
also had anthropometric measurements (weight, height, 
waist and hips).
The survey excluded adolescents who also had 
significant additional systemic illnesses (e.g. coagulation 
disorders, hyperthyroidism, hypothyroidism, cardiovascular 
disease, diabetes, peptic ulcer, autoimmune diseases, other 
endocrine disorders, epilepsy). The study did not include 
females who were taking hormonal or contraceptive pills, 
non-steroidal anti-inflammatory drugs or have been on 
a restrictive diet in the last six months. 
The examined adolescents in the early follicular phase 
of the menstrual cycle (between the 3rd and 5th day of the 
menstrual cycle), between 8:00 am and 9:00 am fasting, 
16 hours after their last meal, had 15 mL of venous blood 
for biochemical markers taken.
Measurements of serum levels of glucose, total 
cholesterol, LDL cholesterol, HDL cholesterol and 
triglycerides were made by colorimetric method (COBAS 
e 411 Roche), while immunoenzymatic assays (ELISA) were 
used for determination of serum levels of DHEA-S, FSH, LH, 
insulin, SHGB, total testosterone, androstenedione and free 
testosterone. 
Insulin resistance was assessed by an indirect method 
based on the results obtained after calculating the index 
value HOMA-IR = insulin concentration in the serum of 
fasting (mIU/mL) × fasting plasma glucose levels (mmol/L) 
/22.5 [18].
The free androgen index (FAI) was calculated in ac-
cordance with the standard formula (FAI = [total testoster-
one/SHBG] × 100%).
Statistical analysis
The statistical tests were conducted using computer 
software Excel 2007 and STATISTICA 10. The results of the 
survey were considered statistically significant when p 
values ≤ 0.05.
Data were analyzed using the Mann-Whitney U test, 
Fisher’s exact test and chi-squared test with Yates correction.
RESULTS
General characteristics of the study groups
The group of participants with abnormal uterine bleed-
ing (AUB) and the control group were homogeneous in 
terms of age, height and age at menarche. The statistical 
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significance for body weight, BMI, waist circumference and 
hip circumference, for the mean, standard deviation, and 
median in both groups has been proved. (p-values  were 
respectively: p = 0.03; p = 0.03; p = 0.05; p = 0.04; p = 0.006) 
(Tab. 1).
Analysis of the menstrual cycle and the 
androgens features in both bleeding and control 
groups
The occurrence of regular menstrual cycles (30.23%, 
p = 0.006) was significantly lower in the juvenile bleeding 
group. Also, secondary amenorrhea was significantly more 
likely to be recognized in this group of females (p = 0.03) 
(Tab. 1).
The maximum duration of menstrual bleeding in the 
study group averaged at 18.1 ± 15.5 days, and in the control 
group 6.3 ± 0.6 days (p < 0.000001). In contrast, the shortest 
menstrual bleeding in the group of females with abnormal 
bleeding profile averaged 8.6 ± 5.0 days, respectively, and 
4.9 ± 0.7 in the control group (p < 0.000001) (Tab. 1).
Hirsutism has been significantly more frequently 
observed in the group of bleeding in comparison to the 
control group (51.16% vs. 18.92%, P = 0.003). The length of 
the abnormal hair growth did not differ much between the 
two groups (17.8 ± 6.4 months vs 20.6 ± 9.1 months). There 
were also significant differences between hair loss, acne, and 
sometimes from what occurred these ailments. Although 
in a group of juvenile bleeding acne was relatively more 
frequent (86.05% vs 78.38%), but these differences were 
not statistically significant (p = 0.27). Significant differences 
in the severity scale of acne between the two groups of 
females was observed (p = 0.04). In the group of females 
with abnormal menstrual bleeding seborrhea is also much 
more frequent (60.47% vs 16.22%, p = 0.00005) (Tab. 2).
Pelvic ultrasound scan examination 
Pelvic ultrasound scan in the examined females was 
performed between the 3rd and 5th days of the menstrual 
cycle. In the juvenile bleeding group, the mean volume of 
the right ovary was 6.5 ± 2.8 cm3, while in the control group 
5.1 ± 2.4 cm3 (p = 0.03). The average volume of left ovary 
was 6.2 ± 2.7 cm3 of the test group and 4.7 ± 2.8 cm3 for the 
control group (p = 0.01). (Tab. 3).
Hormones and metabolic parameters in blood 
serum
FSH levels in serum were significantly lower in the group of 
bleeding adolescents than in the control group, while the LH 
concentrations in blood serum showed no difference between 
the two groups. The ratio of LH / FSH in the group of females with 
juvenile bleeding was 1.34 ± 0.95 and 0.92 ± 0.39 respectively 
for the control group. These differences were not statistically 
Table 1. General characteristics and course of the menstrual cycles in both study and control group (mean ± SD, median, 5th percentile, 95th 
percentile)
Study group Control group p
Age [years] 15.3 ± 1.6[16.0] (13.0; 18.0)
15.6 ± 1.6
[16.0] (13.0; 18.0) NS (p = 0.50)
a
Height [cm] 163.2 ± 6.1[163] (151; 172)
163.6 ± 5.0
[164] (155; 172) NS (p = 0.84)
a
Weight [kg] 56.8 ± 10.4[55.0] (45.1; 75.3)
61.7 ± 10.4
[57.8] (50.0; 81.0) p = 0.03
a
BMI 21.4 ± 3.9[20.4] (16.5; 28.8)
22.9 ± 3.5
[22.0] (19.0; 30.7) p = 0.03
a
Waist circumference [cm] 70.7 ± 7.8[68.5] (61.1; 84.9)
74.5 ± 8.6
[72.0] (65.5; 93.0) p = 0.04
a
Hip circumference [cm] 93.3 ± 8.1[92.0] (84.0; 107.7)
98.5 ± 7.5
[97.5] (84.5; 110.1) p = 0.006
a
Menarche [age] 12.6 ± 1.2[12] (11.0; 15.0)
13.0 ± 1.0
[13] (11.8; 14.2) NS (p = 0.06)
a
The longest bleeding in the last 6 months [days] 18.1 ± 15.5[11] (8; 55)
6.3 ± 0.6
[6] (6; 7) p < 0.000001
a
The shortest bleeding in the last 6 months [days] 8.6 ± 5.0[7] (4; 15)
4.9 ± 0.7
[5] (4; 6) p < 0.000001
a
Irregular cycles occurrence % 69.77 40.54 p = 0.006b
Secondary amenorrhea % 30.23 10.81 p = 0.03b
Statistical tests: 
a — Mann-Whitney U test 
b — Chi-squared test with Yates correction test
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significant (p = 0.15). There were no statistically significant 
differences in concentrations of DHEA-S, free testosterone, 
total testosterone, androstenedione, and SHBG. The value 
of the FAI also did not differ statistically significant between 
the two groups (Tab. 4).
The group of females with juvenile bleeding and the 
control group did not differ in levels of: total cholesterol, 
triglycerides and HDL cholesterol fractions in blood 
serum. Insulin concentrations in serum did not differ 
significantly, although in the test group showed a generally 
higher concentration (10.02 ± 5.02 uU/mL) than controls 
(7.62 ± 4.11 uU/mL). LDL lipoprotein cholesterol in serum 
was much lower in the treatment group (78.6 ± 19.8 mg/dL) 
than in the control group (86.0 ± 22.3 mg/dL). Serum 
glucose levels were significantly higher in the test 
group (4.66 ± 0.29 nmol/L) than in the control group 
(4.09 ± 0.80 nmol/L). Importantly it was found that the value 
of HOMA-IR was statistically higher in the group of females 
with juvenile bleeding (2.10 ± 1.04) than in the control group 
(1.49 ± 0.79) (Tab. 4). 
In the group of females with abnormal uterine bleeding, 
insulin resistance by HOMA-IR ≥ 2.5 was diagnosed 
significantly more often than in healthy females (26.19% 
versus 5.26%), (Fig. 1).
PCOS occurrence in bleeding and control groups
PCOS occurred more often when bleeding was of at least 
moderate intensity (33.33% of this group). However in the 
group with mild bleeding, PCOS occurrence was 9.52% and 
in the control group, occurrence was only 5.41% (Fig. 2).
Table 2. Analysis of the androgenization features occurrence and the size of the ovaries in both study and control group (mean ± SD, median, 
5th percentile, 95th percentile)
Study group Control group p
Hirsutism occurrence 22 (51.16%) 7 (18.92%) p = 0.003a
Length of hirsutism occurrence [months] 17.8 ± 6.4[18] (8.2; 24.0)
20.6 ± 9.1
[24] (12.0; 32.4) NS (p = 0.53)
b
Ferriman-Gallwey score
[points]
10.3 ± 2.5
[9] (8; 15)
10.1 ± 1.6
[10] (8; 12) NS (p = 0.75)
b
Hair loss 7 (16.28%) 2 (5.41%) NS (p = 0.12)a
Acne 37 (86.05%) 29 (78.38%) NS (p = 0.27)a
Acne occurrence [months] 37.8 ± 16.6[36] (17; 53]
32.0 ± 12.5
[30] (18; 49) NS (p = 0.17)
b
The severity scale of acne [points] 4.5 ± 2.3[4] (1; 8)
3.3 ± 1.8
[3] (1; 7) p = 0.04
b
Seborrhoea 26 (60.47%) 6 (16.22%) p = 0.00005a
Statistical tests: 
a — Fisher’s Exact Test  
b — Mann-Whitney U test
Table 3. The results of analysis of ultrasound scan in both study and the control group (mean ± SD, median, 5th percentile, 95th percentile)
Study group Control group p
The size of the right ovary [cm3] 6.5 ± 2.8[5.9] (2.6; 11.9)
5.1 ± 2.4
[4.3] (2.8; 9.0) p = 0.03
a
The size of the left ovary [cm3] 6.2 ± 2.7[6.6] (2.6; 11.3)
4.7 ± 2.8
[3.5] (1.8; 9.1) p = 0.01
a
Endometrium length [cm] 0.73 ± 0.22[0.75] (0.42; 1.00]
0.54 ± 0.17
[0.55] (0.29; 0.80] p = 0.003
a
Length of uterus [cm] 3.63 ± 0.62[3.60] (2.72; 4.51)
3.28 ± 0.58
[3.37] (2.50; 4.12) NS (p = 0.06)
a
Length of cervix [cm] 2.97 ± 0.57[2.80] (2.29; 3.97)
2.84 ± 0.46
[2.80] (2.20; 3.55) NS (p = 0.44)
a
Ratio of uterus and cervix length 1.24 ± 0.21[1.24] (0.93; 1.65)
1.16 ± 0.09
[1.12] (1.06; 1.33) NS (p = 0.10)
a
Statistical tests: 
a — Mann-Whitney U test
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DISCUSSION
The average duration of menstrual bleeding within 
the group of females with heavy menstrual bleeding was 
18.1 ± 15.5 days, and the range was high, (8 to 55 days, 
between the 5th and 95th percentiles). This demonstrated 
a complex clinical picture of juvenile bleeding.
Table 4. The concentration of hormones in the blood serum, and metabolic parameters in both test and control group (mean ± SD, median 5th 
percentile, 95th percentile)
Study group Control group p
FSH [mIU/mL] 5.09 ± 1.51[4.89] (2.14; 7.46)
7.49 ± 3.03
[7.15] (3.16; 11.91) p = 0.0002
a
LH [mIU/mL] 6.60 ± 4.84[5.10] (2.46; 18.53)
6.77 ± 3.85
[6.19] (1.37; 11.82) NS (p = 0.59)
a
LH/FSH 1.34 ± 0.95[1.01] (0.47; 3.21)
0.92 ± 0.39
[0.95] (0.34; 1.61) NS (p = 0.15)
a
DHEA-S [μg/dL] 252.6 ± 96.2[244.1] (107.5; 419.4)
212.6 ± 87.7
[198.1] (81.4 346.7) NS (p = 0.13)
a
Free testosterone [pg/mL] 3.69 ± 6.72[2.02] (0.64; 11.45)
2.17 ± 1.52
[1.97] (0.64; 3.40) NS (p = 0.53)
a
Total testosterone [ng/mL] 0.33 ± 0.17[0.29] (0.12; 0.62)
0.26 ± 0.1
[0.28] (0.09; 0.42) NS (p = 0.19)
a
Androstenedione [ng/mL] 2.56 ± 1.46[2.24] (1.11; 5.23)
2.23 ± 0.77
[2.31] (1.24; 2.86) NS (p = 0.60)
a
SHGB [nmol/L] 59.78 ± 31.55[55.07] (23.61; 108.4)
53.03 ± 14.69
[51.35] (32.08; 76.82) NS (p = 0.64)
a
FAI 0.81 ± 0.77[0.59] (0.14; 2.27)
0.53 ± 0.27
[0.48] (0.21; 0.91) NS (p = 0.44)
a
Total cholesterol [mg/dL] 139.4 ± 25.1[136] (97; 183)
146.5 ± 26.0
[146] (96; 191) NS (p = 0.18)
a
Triglycerides [mg/dL] 83.2 ± 30.3[82] (38; 136)
83.2 ± 44.5
[67] (41; 190) NS (p = 0.26)
a
HDL [mg/dL] 51.9 ± 12.8[51] (35; 72)
51.0 ± 14.9
[48] (31; 86) NS (p = 0.48)
a
LDL [mg/dL] 78.6 ± 19.8[95] (56; 126)
86.0 ± 22.3
[86] (55; 124) p = 0.001
a
Glucose (nmol/L) 4.66 ± 0.29[4.60] (4.30; 5.28)
4.09 ± 0.80
[4.24] (3.35; 4.74) p < 0.000001
a
Insulin [μU/mL] 10.02 ± 5.02[8.86] (3.92; 19.46)
7.62 ± 4.11
[6.76] (3.49; 11.75) NS (p = 0.53)
a
HOMA-IR 2.10 ± 1.04[1.86] (0.89; 4.32)
1.49 ± 0.79
[1.27] (0.72; 2.33) p = 0.01
a
Statistical tests: a – Mann-Whitney U test
HOMA-IR ≥ 2.5 HOMA-IR < 2.4
Study group
Test p = 0,05
26.19%
Control group
73.81%
5.26%
94.74%
PCOS present PCOS absent
Mild bleeding
p = 0.05
9.52%
Moderate intensity bleeding Control group
90.48%
5.41%
66.67%
33.33%
94.59%
Figure 1. Insulin resistance measured by HOMA-IR in the study and 
control group. Statistical tests: Fisher’s Exact Test
Figure 2. Frequency of PCOS in both test and control 
groups. Statistical tests: Mann-Whitney U test
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The limited existing research in young females with 
heavy and prolonged menstrual bleeding does not allow 
comparison of the results of this study with other studies 
accurately. 
For instance, one study conducted in a group of young 
Turkish females with heavy menstrual bleeding also as-
sessed the duration. This included 31 females who were 
diagnosed with abnormal uterine bleeding (AUB) and ane-
mia, with an average age of 15.3 years (12–19 years). Their 
results were similar to those in this study; demonstrating 
a large discrepancy in the length of menstrual bleeding 
(4–90 days). The average length of menstrual bleeding was 
22.6 ± 20.0 days. The limitation of these results is, unfortu-
nately, a small study group [23].
Our study showed AUB was significantly more frequent 
in the group of females with juvenile bleeding in comparison 
the control group (p = 0.006). AUB was diagnosed in 69.77% 
of females with juvenile bleeding, whereas 59.46% of females 
in the control group had a regular menstrual period. This 
study also highlighted the presence of secondary amenor-
rhea among the surveyed females, being diagnosed more 
frequently in the group of females with AUB (p = 0.03) [24].
Similar observations were obtained by a study of Brazil-
ian females aged between 12–19 years old. It is worth noting 
that only females who were at least 2 years after menarche 
qualified for this particular study. Out of all the participants, 
more than half (61%) had irregular menstrual cycles and 
69% were diagnosed with PCOS. Secondary amenorrhea 
was identified in 13.56% of all females who have taken part 
in this study [25].
A study by Shah et al. [26] also showed a high frequency 
of irregular menstrual cycles among young females (50.9%), 
and 29.4% of teenagers had secondary amenorrhea (ab-
sence of menstrual bleeding for > 3 months).
Our study also found that more than half of females 
diagnosed with juvenile bleeding (51.16%) also had 
hirsutism. An increased incidence of acne was also observed 
(86.05%), and the scale of severity was significantly higher 
compared to the control group (p = 0.04). Females with 
juvenile bleeding experienced seborrhea significantly 
more often compared to the control group (p = 0.00005). 
These results indicate a higher occurrence of features 
of androgenization in the group experiencing juvenile 
bleeding. This group may be more prone to developing 
PCOS in adolescence or adulthood (in adolescence some 
females may not present the complete clinical picture of 
the disease).
Hyperandrogenism (or androgen excess) in young fe-
males has been the subject of several studies. The example 
of this is a prospective cohort study conducted in Finland 
with a large population of females, confirmed that hyper-
androgenism in adolescence was associated with a higher 
incidence of PCOS in adulthood. West et al., conducted 
a study on a group of 2.448 females aged between 15 and 
16 years old. They assessed the occurrence of PCOS, hir-
sutism, acne and pregnancy problems in a group of females 
after 10 years of follow-up. The study found that females 
with irregular menstrual cycles at the age of 16 also ex-
perienced significantly more skin problems, such as acne 
and hirsutism, at age 26, compared to females with regular 
menses (p = 0.049). The study also found that adult women 
with PCOS had significantly higher serum testosterone 
levels (p = 0.011) and higher FAI (p = 0.013) in adolescence 
compared to the group with regular menses. Similarly, 
women with hirsutism aged 16 presented significantly low-
er concentrations of SHBG in the blood serum (p = 0.003) 
and higher FAI (p = 0.001). Also, women with a history of 
acne also had significantly higher levels of testosterone 
(P = 0.041), higher FAI (p < 0.001) and significantly lower 
levels of SHBG (p = 0.003) compared to women without 
a history of acne [27].
On the other hand, a study by Pinola et al. [28] on a large 
group of Finnish females aged 15–16 years confirmed sig-
nificantly higher levels of testosterone (p = 0.0010), lower 
levels of SHBG (p = 0.042) and higher values FAI (p = 0.002) 
in the group of females with irregular menstrual cycles com-
pared to those with regular cycles. These studies show that 
menstrual disorders in adolescence are a possible indicator 
of hyperandrogenism, and may be an early risk factor for 
polycystic ovarian syndrome in adulthood [23].
Analyzing the biochemical parameters between the 
group diagnosed with juvenile bleeding and the control 
groups demonstrated that the concentration of FSH was 
significantly lower (p = 0.0002) in the juvenile bleeding 
group compared to controls. No significant differences 
in concentrations of DHEA-S, free testosterone, total, 
androstenedione, SHBG and FAI values between the two 
groups of females were found. The glucose concentration 
(p < 0.000001) and the fraction of LDL cholesterol (p = 0.001) 
in blood serum differed significantly between the study 
group and control group. This study also found that the 
value of HOMA-IR was significantly higher (p = 0.01) in the 
juvenile bleeding group than in controls.
It has been hypothesized that young adolescents who 
experience juvenile bleeding are at risk of PCOS. This study 
is supported by the current research available. PCOS was 
more often diagnosed in the group with abnormal men-
strual bleeding. There was also a correlation between the 
severity of bleeding and the incidence of PCOS syndrome. 
PCOS was more often diagnosed in the group of moder-
ate and severe bleeding (33.3%). In the group with mild 
bleeding PCOS was diagnosed in 9.24% of the females, 
while in the control group it was diagnosed in 5.41% of 
females (p = 0.05). These studies differ slightly from the 
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results of the Basaran et al. on the Turkish population of fe-
males with heavy menstrual bleeding. This study involved 
36 young females (mean age 13.7 ± 1.4 years) diagnosed 
with juvenile bleeding. Only one patient was diagnosed 
with PCOS (2.8%). However, 25% of the study group of 
females were diagnosed with coagulation disorders [23]. 
It would appear that the differences between our studies 
and those conducted in Turkey are due to the different 
etiologies of heavy menstrual bleeding. Unfortunately, in 
the study by Basaran et al., there is no information about 
the duration of menstrual cycles, relation of LH/FSH and 
diagnostic criteria used for diagnosis of PCOS. It was there-
fore difficult to determine whether abnormal menstrual 
bleeding was connected to the lack of ovulation, and to 
what extent [23].
Vrbikova et al. [29], studied the prevalence of metabolic 
syndrome among Czech young females with PCOS and 
demonstrated that juvenile bleeding occurred in 6.97% of 
teens with PCOS. This American study also confirmed the 
presence of heavy menstrual bleeding in adolescent females 
with PCOS (3.9%) [26].
Literature available about the presence of PCOS in 
groups of females with the juvenile bleeding is limited. 
Few studies show the existence of PCOS in this group, but 
do not define a direct relation between juvenile bleeding 
and PCOS [23, 26, 29]. 
There were some limitations in this research which may 
affect its interpretation. The first limitation was the relatively 
small number of cases. This makes it more difficult to gen-
eralize findings to the entire group of females with juvenile 
bleeding, and the results should be treated as preliminary. 
Another limitation of the study was that the assessment of 
menstrual cycles and the duration of menstrual bleeding 
were retrospective in nature and therefore their assessment 
may have been less accurate.
Despite these limitations of the study, its novel findings 
should be highlighted, and the results should be considered 
as preliminary to extend the research on a larger population 
of females. To assess the long-term consequences of juvenile 
bleeding in adolescence, a prospective cohort study assess-
ing the health of the same study group when they are fully 
mature should be also carried out. 
CONCLUSIONS
Juvenile bleeding may be a risk factor of PCOS. The au-
thors recommend performing screening studies in females 
with a high degree of risk for the development of polycystic 
ovarian syndrome, such as irregular menstrual cycles, the 
occurrence of excessive male type hair and acne. Such meas-
ures may reduce the risk of developing metabolic disorders 
and consequently improve the long-term health of young 
women [20, 30–32]. 
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